IVI and Mozambique


Ongoing Collaboration


Expanding COVID-19 Vaccine Access and Delivery in Africa (ECOVA) 1 & 2

ECOVA-01 is a Phase 3 randomized, observer-blind, controlled trial to assess the efficacy, immunogenicity, and safety of BBIBP-CorV vaccine against SARS-CoV-2 infection.


ECOVA-02 is a phase 2, observer-blind, randomized study to assess the safety, tolerability and immunogenicity of heterologous prime-boost COVID-19 vaccines regimens in healthy adults aged 18 to 65 years in Mozambique. ECOVA-02 is a mix and match study using the Sinopharm and Johnson & Johnson vaccines. 


ECOVA 01 and 02 are conducted in cooperation with Mozambique’s Instituto Nacional de Saúde (INS).


Mozambique Typhoid Fever Surveillance (MOTIF) Program

Since 2020, IVI’s MOTIF program has been supporting efforts by the government of Mozambique to introduce typhoid conjugate vaccine (TCV) into their national immunization schedule by generating typhoid fever disease burden data. MOTIF works in close collaboration with INS and is funded by a donation from Professor Young Chul Sung of Korea’s POSTECH. 


Enhancing Cholera Control (ECHO) – Mozambique

Since 2020, IVI’s ECHO program has been conducting a major cholera control and prevention project in Mozambique, which included oral cholera vaccine (OCV) vaccination campaigns combined with Water, Sanitation, and Hygiene (WASH) activities, disease surveillance, and the development and approval of a National Cholera Control Plan. IVI works in close collaboration with INS and the Ministry of Health of Mozambique with funding from the Korean International Cooperation Agency’s Global Disease Eradication Fund, LG Electronics, and the Korean Support Committee for IVI. 


Previous Collaboration


Mozambique Cholera Prevention and Surveillance (MOCA) {embedded YouTube video player possible?}

From 2018 to 2020, IVI’s MOCA program worked to prevent cholera epidemics and empower local public health services for sustainable cholera surveillance and control. In 2018, MOCA administered OCV to approximately 180,000 individuals living in Cuamba district. This vaccination campaign was followed by vaccination monitoring and evaluation, disease surveillance studies, health economics analysis, and WASH education. 


Mass Oral Cholera Vaccination in Beira, Mozambique


From 2003 to 2004, as part of the Disease of the Most Impoverished (DOMI) program, IVI conducted a mass vaccination campaign in the Esturro neighborhood of Beira, Mozambique using the Dukoral OCV. Approximately 14,164 individuals, or 72% of the qualified local population received one dose of Dukoral, while 11,070 individuals or 57% of the qualified local population received two doses of the Dukoral vaccine. 


Following vaccination, disease surveillance and follow-up studies demonstrated that the vaccine conferred 78% to 84% protection against cholera infection. IVI collaborated closely with the Centros de Tratamento de Colera and the Centro de Higiene Ambiental e Exames Médecos in Beira, Médecins Sans Frontières, and the Ministry of Health of Mozambique, and the program was funded by the Bill and Melinda Gates Foundation.